CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 130 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2020. The put-call ratio across all filers is 0.95 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,366,824 | -18.9% | 122,341 | -0.0% | 2.26% | -19.8% |
| Q2 2023 | $4,151,098 | -5.0% | 122,343 | +0.7% | 2.81% | -12.7% |
| Q1 2023 | $4,371,570 | -14.7% | 121,500 | +5.7% | 3.22% | +2.1% |
| Q4 2022 | $5,125,550 | -31.8% | 115,000 | -57.0% | 3.15% | -2.5% |
| Q3 2022 | $7,511,000 | +4.3% | 267,195 | 0.0% | 3.23% | -19.4% |
| Q2 2022 | $7,204,000 | -34.5% | 267,195 | -17.3% | 4.01% | -21.9% |
| Q1 2022 | $10,998,000 | -16.3% | 322,898 | -5.1% | 5.14% | -7.0% |
| Q4 2021 | $13,141,000 | -27.9% | 340,098 | +0.8% | 5.52% | -14.1% |
| Q3 2021 | $18,222,000 | -63.4% | 337,500 | -77.3% | 6.43% | -67.7% |
| Q2 2021 | $49,739,000 | +137.3% | 1,487,406 | +46.2% | 19.88% | +163.0% |
| Q1 2021 | $20,961,000 | -26.5% | 1,017,524 | -37.5% | 7.56% | -2.6% |
| Q4 2020 | $28,514,000 | +24.5% | 1,627,500 | +5.3% | 7.76% | +24.7% |
| Q3 2020 | $22,912,000 | +76.2% | 1,545,000 | +54.5% | 6.22% | +65.7% |
| Q2 2020 | $13,000,000 | – | 1,000,000 | – | 3.76% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |